Skip to main content
AAN.com
Research Article
March 21, 2022
continuing medical education

Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment

May 17, 2022 issue
98 (20) e2036-e2045
Letters to the Editor

Abstract

Background and Objectives

To identify clinicopathologic factors contributing to mild cognitive impairment (MCI) reversion to normal cognition.

Methods

We analyzed 3 longitudinal cohorts in this study: the Mayo Clinic Study of Aging (MCSA), the Religious Orders Study and Memory and Aging Project (ROSMAP), and the National Alzheimer's Coordinating Center (NACC). Demographic characteristics and clinical outcomes were compared between patients with MCI with or without an experience of reversion to normal cognition (referred to as reverters and nonreverters, respectively). We also compared longitudinal changes in cortical thickness, glucose metabolism, and amyloid and tau load in a subcohort of reverters and nonreverters in MCSA with MRI or PET imaging information from multiple visits.

Results

We identified 164 (56.4%) individuals in MCSA, 508 (66.8%) individuals in ROSMAP, and 280 (34.1%) individuals in NACC who experienced MCI reversion to normal cognition. Cox proportional hazards regression models showed that MCI reverters had an increased chance of being cognitively normal at the last visit in MCSA (HR 3.31, 95% CI 2.14–5.12), ROSMAP (HR 3.72, 95% CI 2.50–5.56), and NACC (HR 9.29, 95% CI 6.45–13.40) and a reduced risk of progression to dementia (HR 0.12, 95% CI 0.05–0.29 in MCSA; HR 0.41, 95% CI 0.32–0.53 in ROSMAP; and HR 0.29, 95% CI 0.21–0.40 in NACC). Compared with MCI nonreverters, reverters had better-preserved cortical thickness (β = 0.082, p <0.001) and glucose metabolism (β = 0.119, p = 0.001) and lower levels of amyloid, albeit statistically nonsignificant (β = −0.172, p = 0.090). However, no difference in tau load was found between reverters and nonreverters (β = 0.073, p = 0.24).

Discussion

MCI reversion to normal cognition is likely attributed to better-preserved cortical structure and glucose metabolism.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Bos I, Vos S, Verhey F, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimers Dement. 2019;15(5):644-654.
2.
Lleó A, Alcolea D, Martínez-Lage P, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019;15(6):742-753.
3.
Guo T, Korman D, Baker SL, et al. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology. Biol Psychiatry. 2021;89(8):786-794.
4.
Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397-405.
5.
Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447-1455.
6.
Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312(23):2551-2561.
7.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.
8.
Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992.
9.
Aerts L, Heffernan M, Kochan NA, et al. Effects of MCI subtype and reversion on progression to dementia in a community sample. Neurology. 2017;88(23):2225-2232.
10.
Canevelli M, Grande G, Lacorte E, et al. Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta-analysis. J Am Med Dir Assoc. 2016;17(10):943-948.
11.
Roberts RO, Knopman DS, Mielke MM, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82(4):317-325.
12.
Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology. 2012;79(15):1591-1598.
13.
Sachdev PS, Lipnicki DM, Crawford J, et al. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. PLoS One. 2013;8(3):e59649.
14.
Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69.
15.
Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders study and Rush memory and aging Project. J Alzheimers Dis. 2018;64(s1):S161–s189.
16.
Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21(3):249-258.
17.
Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status: correlations with standardized psychometric testing. Arch Neurol. 1991;48(7):725-728.
18.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
19.
Jack CR, Jr., et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13(3):205-216.
20.
Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2020.
21.
Ganguli M, Snitz BE, Saxton JA, et al. Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol. 2011;68(6):761-767.
22.
Thomas KR, Edmonds EC, Eppig JS, et al. MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2019;15(10):1322-1332.
23.
Pacheco J, Goh JO, Kraut MA, Ferrucci L, Resnick SM. Greater cortical thinning in normal older adults predicts later cognitive impairment. Neurobiol Aging. 2015;36(2):903-908.
24.
Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 2006;129(Pt 11):2885-2893.
25.
Márquez F, Yassa MA. Neuroimaging biomarkers for Alzheimer's disease. Mol Neurodegener. 2019;14(1):21.
26.
Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72(12):1048-1055.
27.
Eskildsen SF, Coupé P, García-Lorenzo D, Fonov V, Pruessner JC, Collins DL. Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage. 2013;65:511-521.
28.
Hammond TC, Xing X, Wang C, et al. β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. Commun Biol. 2020;3(1):352.
29.
Pagani M, Nobili F, Morbelli S, et al. Early identification of MCI converting to AD: a FDG PET study. Eur J Nucl Med Mol Imaging. 2017;44(12):2042-2052.
30.
Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218.
31.
Perani D. FDG-PET and amyloid-PET imaging: the diverging paths. Curr Opin Neurol. 2014;27(4):405-413.
32.
Dufouil C, Godin O, Chalmers J, et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke. 2009;40(6):2219-2221.
33.
Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham study. Stroke. 2004;35(6):1264-1268.
34.
Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020;15(1):63.
35.
Dumitrescu L, Mahoney ER, Mukherjee S, et al. Genetic variants and functional pathways associated with resilience to Alzheimer's disease. Brain. 2020;143(8):2561-2575.
36.
Yu L, Tasaki S, Schneider JA, et al. Cortical proteins associated with cognitive resilience in community-dwelling older persons. JAMA Psychiatry. 2020;77(11):1172-1180.

Information & Authors

Information

Published In

Neurology®
Volume 98Number 20May 17, 2022
Pages: e2036-e2045
PubMed: 35314499

Publication History

Received: September 22, 2021
Accepted: February 1, 2022
Published online: March 21, 2022
Published in print: May 17, 2022

Permissions

Request permissions for this article.

Disclosure

G. Bu consults for SciNeuro and Lexeo; has consulted for AbbVie, E-Scape, Eisai, and Vida Ventures; is on the scientific advisory board for Kisbee Therapeutics; and receives funding from NIH and Cure Alzheimer's Fund. G.S. Day's research is supported by NIH, the Alzheimer's Association, and Chan Zuckerberg Initiative; he consults for Parabon Nanolabs Inc., as a Topic Editor (Dementia) for DynaMed (EBSCO) and as the Clinical Director of the Anti-NMDA Receptor Encephalitis Foundation (Canada; uncompensated); is the co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from Horizon Pharmaceuticals; has developed educational materials for PeerView Media, Inc., and Continuing Education Inc.; and owns stock in ANI Pharmaceuticals. M. Vassilaki has received research funding from F. Hoffmann-La Roche and Biogen. She currently consults for F. Hoffmann-La Roche, receives research funding from NIH and has equity ownership in Abbott Laboratories, Johnson & Johnson, Medtronic, and Amgen. R. Petersen consults for Nestle, Merck, Roche, Biogen, and Eisai; and is on the Data Safety Monitoring Board of Genentech. The remaining authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

The MCSA cohort was supported by the NIH (U01 AG006786, P50 AG016574, P30 AG062677, R01 AG011378, R01 AG041851, R01 NS097495), the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic, the Liston Award, the Schuler Foundation, the GHR Foundation, and the Mayo Foundation for Medical Education and Research and was made possible by the Rochester Epidemiology Project (R01 AG034676). The ROSMAP cohort was supported by NIA grants P30AG10161, R01AG15819, and R01AG17917. The NACC cohort was supported by NIA/NIH grant U01 AG016976. NACC data are contributed by the NIA-funded ADRCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD). This work is partially supported by the NIH grants RF1AG057181, R37AG027924, and RF1AG046205, and a Cure Alzheimer's Fund grant to G.B. and the Coins for Alzheimer's Research Trust (CART) Foundation to N.Z. The funders had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Authors

Affiliations & Disclosures

From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Michael G. Heckman, MS
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Parkinsonism and Related Disorders, Editorial board, 2013- current
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NIA RF1-AG071226-01 Kanekiyo (PI) 03/15/2021-02/29/2024 NIH/NIA RF1-AG068034-01A1 Kanekiyo (Co-PI) 05/15/2021-04/30/2024 NIH/NIA U19-AG069701-01: 8364 Kanekiyo (Core leader/Biomarker Core) 06/01/2021-05/31/2026 NIH/NIA R01-AG051574-01 Kanekiyo (Co-PI) 09/01/2016-5/31/2022 NIH/NIA R56-AG062620 Kanekiyo (Co-PI) 09/15/2019- 06/30/2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Cure Alzheimer's Fund Kanekiyo (PI) 02/01/2020- 01/31/2022
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Continuing Education Company, Honoraria + travel for CME activities
Editorial Boards:
1.
1. DynaMed, EBSCO; ad-hoc Dementia Topic Editor for online evidence-based medicine resource; 2016-ongoing. 2. Associate Editor, Journal of Alzheimer's Disease 3. Level of Evidence Rater, Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1. Parabon Nanolabs, Inc (advice / support on NIH-funded project).
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1. Biogen: Involved in clinical trials of anti-amyloid agents (no direct payments; research agreement between sponsor and institution).
Research Support, Government Entities:
1.
1. NIH/NIA: K23AG064029, PI, 2019-2024 2. NIH/NIA: U01AG057195, site-PI, 2021- 3. NIH/NIA: U19AG032438, site-PI, 2021
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1. Chan Zuckerberg Foundation (Neurodegenerative Challenge Network), CS-0000000472, Clinical PI, 2019-2022 2. Alzheimer's Association (Grant to promote diverse recruitment in LEADS; PI, 2021-22)
Stock/stock Options/board of Directors Compensation:
1.
1) Hold stocks (>$10,000) in ANI Pharmaceuticals (a generic pharmaceutical company; 2015 onward). 2) Parabon Nanolabs, Inc (stock options).
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Maria Vassilaki, MD, PhD https://orcid.org/0000-0001-8328-136X
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of Alzheimer's Disease, Associate Editor (2019-present); (2) Frontiers in Neuroscience (Neurodegeneration) Guest Editor for Research Topic collection “Multimorbidity in the Context of Neurodegenerative Disorders” (2021-present) and (3) Frontiers in Aging Neuroscience, Guest Editor for Research Topic collection “Multimorbidity in the Context of Neurodegenerative Disorders” (2021-present)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) F. Hoffmann-La Roche Ltd (payment submitted to my institution)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) F. Hoffmann-La Roche Ltd; (2) Biogen; (3) (for spouse K. Papadakis) Avobis Bio, LLC.
Research Support, Government Entities:
1.
1) NIA, AG057708, co-Investigator and site PD/PI, 2018- present (2) NIA U01 AG06786, co-Investigator, 2019-present (3) NIA, RF1 AG057181, co-Investigator, 2018-present (4) NIA, R01 AG060920, co-Investigator, 2019-present (5) NIA, R01 AG068192, co-Investigator, 2020-present (6) NIA, R01 AG068007, co-Investigator, 2020-present
Research Support, Academic Entities:
1.
(1) St. Anne's University Hospital Brno, International Clinical Research Center, Czech Republic/EU
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
I and spouse (K. Papadakis) have stocks in (1) Abbott Laboratories (2020-present); (2) Johnson and Johnson (2018- present); (3) Medtronic (2020-present); and (4) Amgen (2019- present).
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
(1) Vigorous Minds, Scientific Advisory Board (3) EABs: India Institute of Science; MCSA; Columbia ADRC; CCNA; CIMA-Q, WFU, Emory, MODEL-AD, REGARDS, ADD Health, Dunedin Study, MCSA, NAD RCMAR, MEMCARE, ASPREE (4) DMCs: HRS, MIDUS, Dunedin Study (5) National Advisory Council on Aging
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Neurology, Editorial Board; (2) Current Alzheimer Research, Editorial Board; (3) Neuroepidemiology, Editorial Board (4) Journal of the Prevention of Alzheimer's Disease, Editorial Board (5) Journal of Alzheimer's Disese (5) Journal of Alzheimer's Disease, Editorial Board (6) Alzheimer's & Dementia: Translational Research & Clinical Interventions, Editorial Board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant, Origent Data Sciences NIH SBIR grant AbbVie DSMB Takeda Adjudication Committee
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Neurovision - amyloid eye imaging
Research Support, Government Entities:
1.
NIH: P30AG72975, PI; P30AG72975, PI; R01AG15819, PI; R01AG17917, PI; R01AG36042, MPI; R01AG54058, PI; U01AG61356, MPI; R01AG52476, MPI;
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ronald C. Petersen, MD, PhD https://orcid.org/0000-0002-8178-6601
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
Genentech - DSMB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Mild Cognitive Impairment,Oxford University Press, 2003 UpToDate
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-2018) U01-AG024904 (Site PI) (2004-present) U24-AG057437 (Co-PI) (2018-present) P30 AG062677 (PI) (2019 - present) U01NS 125417 (Site PI) (2021 &#x00C2;&#x0096; present)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) GHR Foundation, (2) Mayo Medical Foundation for Education and Research, (3) Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
(1) NIH/NIA R01AG066395-01, Bu/Zhao (MPI), 02/01/2020 ∼ 12/31/2024 (2)NIH/NIA U19AG06970, Bu/Holtzman/Goate (MPI), Zhao (co- leader for Core B), 04/01/2021 ∼ 02/28/2026 (3) Mayo Clinic ADRC developmental grant AG62677-03 DEV, Zhao (PI), 05/01/2021 ∼ 04/30/2023
Research Support, Foundations and Societies:
1.
(1) BrightFocus Foundation Grant A2021046S, Zhao (PI), 07/01/2021 ∼ 06/30/2024
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Disclosure
Scientific Advisory Boards:
1.
1) Scientific advisory board for Kisbee Therapeutics
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1) SciNeuro, 2) Lexeo
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) NIH, U19AG069701, Co-PI, 2021-2026 2) NIH, R01AG066395, Co-PI, 2020-2024 3) NIH, P30AG062677, Co-PI for Biomarker Core, 2019-2024 4) NIH, RF1AG046205, PI, 2018-2023 5) NIH, RF1AG057181, PI, 2018-2023 6) NIH, R37AG027924, PI, 2017-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Cure Alzheimer's fund
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Bu [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
*
These authors contributed equally to this work.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Comparison of Brain Amyloid Deposition and Cortical Glucose Metabolism Between Clinic- and Community-Based Cohort, Journal of Alzheimer's Disease, 95, 1, (299-306), (2023).https://doi.org/10.3233/JAD-230550
    Crossref
  2. Roles of traditional chinese medicine regulating neuroendocrinology on AD treatment, Frontiers in Endocrinology, 13, (2022).https://doi.org/10.3389/fendo.2022.955618
    Crossref
  3. Estimating Bidirectional Transitions and Identifying Predictors of Mild Cognitive Impairment, Neurology, 100, 3, (e297-e307), (2022)./doi/10.1212/WNL.0000000000201386
    Abstract
  4. [18F]FDG-PET zur Differenzialdiagnostik und Prognostik der neurodegenerativen Parkinson-Syndrome: Update 2022, Angewandte Nuklearmedizin, 45, 04, (286-296), (2022).https://doi.org/10.1055/a-1712-6125
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share